¼¼°èÀÇ Åõ½Ã ÀåÄ¡ ½ÃÀå
Fluoroscopy Devices
»óǰÄÚµå : 1739144
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 285 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,026,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,080,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Åõ½Ã ÀåÄ¡ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 51¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 41¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Åõ½Ã ÀåÄ¡ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 4.0%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 51¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °íÁ¤½Ä Åõ½Ã Ä«¸Þ¶ó´Â CAGR 3.3%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 34¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À̵¿½Ä Åõ½Ã ÀåÄ¡ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 5.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 11¾ï ´Þ·¯, Áß±¹Àº CAGR7.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Åõ½Ã ÀåÄ¡ ½ÃÀåÀº 2024³â¿¡ 11¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 7.2%·Î ¼ºÀåÇÏ¿©, 2030³â±îÁö 10¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.7%¿Í 3.1%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Åõ½Ã ÀåÄ¡ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Åõ½Ã ÀåÄ¡°¡ Çö´ë ÀÇ·á ¿µ»ó Áø´Ü¿¡¼­ °¢±¤¹Þ´Â ÀÌÀ¯´Â?

Åõ½Ã ÀåÄ¡´Â ¿òÁ÷ÀÌ´Â ³»ºÎ ±¸Á¶¸¦ ¿¬¼ÓÀûÀ¸·Î ¿¢½º·¹ÀÌ·Î °¡½ÃÈ­ÇÒ ¼ö ÀÖ´Â ½Ç½Ã°£ À̹Ì¡ ±â´ÉÀ» °®Ãß°í ÀÖ¾î Àü ¼¼°è ÀÇ·á ¿µ»ó ºÐ¾ß¿¡¼­ ´Ù½Ã ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â ƯÈ÷ ¼øÈ¯±â, Á¤Çü¿Ü°ú, ºñ´¢±â°ú, ¼ÒÈ­±â, ÅëÁõ °ü¸® µîÀÇ Áø´Ü ¹× ÁßÀç ½Ã¼ú¿¡ ÇʼöÀûÀÎ Àåºñ·Î ÀÚ¸®¸Å±èÇϰí ÀÖÀ¸¸ç, CT³ª MRI¿Í °°Àº Á¤ÀûÀÎ ¿µ»ó¹ý°ú ´Þ¸® Åõ½Ã°Ë»ç´Â Á¶¿µÁ¦ÀÇ ¿òÁ÷ÀÓ, Ç÷·ù, ¼ö¼ú ±â±¸ Á¶ÀÛ µî Àǻ簡 »ì¾ÆÀÖ´Â °úÁ¤À» °üÂûÇÒ ¼ö Àֱ⠶§¹®¿¡ Ä«Å×ÅÍ »ðÀÔ, ¹Ù·ý °Ë»ç, Ä«Å×ÅÍ »ðÀÔ, ¹Ù·ý °Ë»ç µî Ä«Å×ÅÍ »ðÀÔ, ¹Ù·ý °Ë»ç, Á¤Çü¿Ü°ú °üÀý Æò°¡ µîÀÇ ½Ã¼ú¿¡ ÇʼöÀûÀÔ´Ï´Ù. ¶ÇÇÑ, ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿µ»ó À¯µµÇÏ ÁßÀç¼ú¿¡¼­ Åõ½Ã °Ë»çÀÇ »ç¿ëµµ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¿Ü»ó Ä¡·á ¹× ÀÀ±Þ ÀÇ·á¿¡¼­ Áï°¢ÀûÀÌ°í ¿ªµ¿ÀûÀÎ À̹ÌÁö¸¦ ¾òÀ» ¼ö ÀÖ¾î º¸´Ù ½Å¼ÓÇϰí Á¤È®ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÆòÆÇ °ËÃâ±â, µðÁöÅÐ À̹ÌÁö ó¸® ¹× ¼±·® °¨¼Ò ±â¼úÀÇ ¹ßÀüÀ¸·Î Åõ½Ã °Ë»çÀÇ ¼±¸íµµ, ¼Óµµ ¹× ¾ÈÀü¼ºÀÌ Å©°Ô Çâ»óµÇ¾î Áø´ÜÀÇ Á¤È®¼º°ú ȯÀÚÀÇ ¾ÈÀüÀ» µ¿½Ã¿¡ Ãß±¸ÇÏ´Â ÀÇ·áÁø¿¡°Ô Åõ½Ã °Ë»ç°¡ ´õ¿í ¸Å·ÂÀûÀ¸·Î ´Ù°¡¿À°í ÀÖ½À´Ï´Ù. À̵¿½Ä C-arm°ú ¼ÒÇü ½Ã½ºÅÛÀÇ ¿Ü·¡ µµÀÔÀ¸·Î Åõ½Ã °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ´õ¿í È®´ëµÇ°í ÀÖÀ¸¸ç, Åõ½Ã °Ë»ç´Â Áö¼ÓÀûÀÎ Ä¡·á¿¡¼­ ÇʼöÀûÀÌ°í ´ÙÀç´Ù´ÉÇÑ µµ±¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ¾î¶»°Ô Á¤È®¼º°ú ȯÀÚ ¾ÈÀüÀ» Çâ»ó½Ã۰í Àִ°¡?

Åõ½Ã °Ë»ç ±â¼úÀÇ Çõ½ÅÀº À̹ÌÁö ǰÁú Çâ»ó, ÇÇÆø¼±·® °¨¼Ò, ÷´Ü ½Ã¼ú µµ±¸¿ÍÀÇ ÅëÇÕÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á Ä¡·á ¼öÁØÀ» ȹ±âÀûÀ¸·Î Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Æò¸é ÆÐ³Î °ËÃâ±â¸¦ žÀçÇÑ µðÁöÅÐ Åõ½Ã ½Ã½ºÅÛÀº ¾Æ³¯·Î±× ½Ã½ºÅÛÀ» ´ëüÇÏ¿© °íÇØ»óµµ, °í¼Ó ó¸®, ¿¬ºÎÁ¶Á÷ÀÇ ´õ ³ªÀº ½Ã°¢È­¸¦ ½ÇÇöÇϰí ÀÖ½À´Ï´Ù. ÆÞ½º Åõ½Ã, ÃÖÁ¾ À̹ÌÁö Ȧµå, ÀÚµ¿ ³ëÃâ Á¦¾î¿Í °°Àº ¼±·® °¨¼Ò ±â´ÉÀº ȯÀÚ¿Í ÀÇ·áÁø ¸ðµÎ¿¡ ´ëÇÑ ¹æ»ç¼± À§Çè¿¡ ´ëÇÑ ¿À·£ ¿ì·Á¸¦ ¿ÏÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ¼ÒÇÁÆ®¿þ¾î °­È­·Î ½Ç½Ã°£ 3D À籸¼º, ¿òÁ÷ÀÓ º¸Á¤, CT ¹× MRI µ¥ÀÌÅÍ¿ÍÀÇ À̹ÌÁö À¶ÇÕÀÌ °¡´ÉÇØÁ® º¹ÀâÇÑ ¼ö¼ú Áß ÇØºÎÇÐÀû Á¤È®µµ°¡ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ³»ºñ°ÔÀÌ¼Ç ½Ã½ºÅÛ ¹× ·Îº¿ ¼ö¼ú Ç÷§Æû°úÀÇ ÅëÇÕÀ» ÅëÇØ Ç÷°ü, ½Å°æ, ôÃß ¼ö¼ú¿¡¼­ Á¤È®ÇÑ Å¸°ÙÆÃÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. À̵¿½Ä C-armÀº ´õ¿í ÄÄÆÑÆ®ÇÏ°í °­·ÂÇØÁ® ¼ö¼ú½Ç, ¿Ü·¡ Áø·á¼Ò ¹× Áö¹æ ÀÇ·á ȯ°æ¿¡¼­µµ ´õ¿í À¯¿¬ÇÏ°Ô ´ëÀÀÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀΰøÁö´ÉÀº ¿öÅ©Ç÷οì ÀÚµ¿È­, ÀÌ»ó ¡ÈÄ °¨Áö, ¿¹Ãø ºÐ¼®¿¡¼­ È¿À²¼º°ú Áø´Ü Á¤È®µµ¸¦ ÃÖÀûÈ­ÇÏ´Â ¿ªÇÒÀ» Çϱ⠽ÃÀÛÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû Áøº¸¸¦ ÅëÇØ Åõ½Ã ÀåÄ¡´Â ¿µ»ó À¯µµ Ä¡·áÀÇ ÃÖÀü¼±¿¡ ¼­¼­ Á¡Á¡ ´õ ´Ù¾çÇØÁö´Â ÀÓ»ó ÇöÀå¿¡¼­ º¸´Ù ¼±¸íÇÑ Áø´Ü°ú ¾ÈÀüÇÑ Ä¡·á °á°ú¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¾î¶² ÀÓ»ó ºÐ¾ß¿Í ¼¼°è ½ÃÀå¿¡¼­ äÅÃÀÌ ÁøÇàµÇ°í Àִ°¡?

Åõ½Ã ÀåÄ¡´Â ±¤¹üÀ§ÇÑ ÀÓ»ó Àü¹® ºÐ¾ß¿Í ÀÇ·á ÇöÀå¿¡¼­ ³ôÀº ¼ö¿ä°¡ ÀÖ½À´Ï´Ù. ÁßÀçÀû ½ÉÀ庴ÇÐ ¹× Àü±â»ý¸®ÇÐÀÌ °¡Àå Å« ºÐ¾ß Áß ÇϳªÀ̸ç, Ç÷°üÁ¶¿µ¼ú, ½ºÅÙÆ® »ðÀÔ ¹× ÀýÁ¦¼ú¿¡ Åõ½Ã°æÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. Á¤Çü¿Ü°ú¿Í ¿Ü»ó¿Ü°ú¿¡¼­´Â °ñÀý ±³Á¤, Àΰø°üÀý ġȯ¼ú, ôÃß ±â±¸ ÀåÂø¿¡ Åõ½Ã °Ë»ç°¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¼ÒÈ­±â³»°ú¿¡¼­´Â ¹Ù·ý »ï۱â, ´ëÀå °Ë»ç, ¿µ¾ç°ü »ðÀÔ¿¡ ÀÌ·¯ÇÑ Àåºñ¸¦ »ç¿ëÇÕ´Ï´Ù. ºñ´¢±â°ú¿Í »êºÎÀΰú¿¡¼­´Â ¿ä°ü ½ºÅÙÆ® »ðÀÔ, Àڱó­°üÁ¶¿µ¼ú µîÀÇ ½Ã¼ú ½Ã ½Ç½Ã°£ ½Ã°¢È­°¡ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÅëÁõ °ü¸® Ŭ¸®´Ð¿¡¼­´Â °æ¸·¿Ü Áֻ糪 ½Å°æÂ÷´Ü¼ú¿¡ Åõ½Ã °¡À̵带 Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖ°í, ½Ã¼ú °Ç¼ö°¡ ¸¹À¸¸ç, ÷´Ü ¿µ»ó ±â¼úÀÌ ºü¸£°Ô º¸±ÞµÇ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. À¯·´Àº Àα¸ °í·ÉÈ­¿Í źźÇÑ °ø°ø ÀÇ·á ½Ã½ºÅÛ¿¡ ÈûÀÔ¾î µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º¿¡¼­ °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº º´¿ø ÀÎÇÁ¶ó È®´ë, ÀÇ·á ±â¼ú¿¡ ´ëÇÑ Á¤ºÎ ÅõÀÚ Áõ°¡, Áß±¹, Àεµ, Çѱ¹ µîÀÇ ±¹°¡¿¡¼­ÀÇ Àúħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î °í¼ºÀå ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿¿¡¼­´Â ƯÈ÷ ¹Î°£ ºÎ¹®ÀÇ ÅõÀÚ ¹× ¹Î°ü ÀÇ·á Çù·ÂÀ» ÅëÇØ Á¡Â÷ µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼¼°è Ãß¼¼´Â ¼±Áø±¹°ú ½ÅÈï±¹ ¸ðµÎ¿¡¼­ ÇコÄÉ¾î »ýŰ迡¼­ Åõ½Ã °Ë»ç¿¡ ´ëÇÑ ¼¼°è È®»ê°ú ½Å·Ú Áõ°¡¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå °¡¼ÓÈ­ÀÇ Áß¿äÇÑ ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

Åõ½Ã ÀåÄ¡ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ½Ã¼ú ¼ö¿ä, ÀÇ·á ¼­ºñ½º Á¦°øÀÇ º¯È­¿¡ ±â¹ÝÇÑ ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ù°, Àü ¼¼°èÀûÀ¸·Î ÃÖ¼Òħ½À ¼ö¼ú ¹× ¿µ»ó À¯µµ ÁßÀç¼úÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¤È®µµ¸¦ ³ôÀ̰í ȸº¹ ½Ã°£À» ´ÜÃàÇÒ ¼ö ÀÖ´Â ½Ç½Ã°£ ¿µ»ó µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µÑ°, ½ÉÇ÷°ü Áúȯ, ¼ÒÈ­±â Áúȯ, ±Ù°ñ°Ý°è Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÏ´Â °í·ÉÈ­·Î ÀÎÇØ Åõ½Ã¹ý¿¡ ÀÇÁ¸ÇÏ´Â Áø´Ü ¹× Ä¡·á ½Ã¼úÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼Â°, µðÁöÅÐ ¿µ»ó, ¹æ»ç¼±·® °ü¸®, À̵¿½Ä Åõ½Ã ½Ã½ºÅÛÀÇ ¹ßÀüÀ¸·Î Åõ½Ã ±â¼úÀÌ ´õ¿í ¾ÈÀüÇϰí, 3Â÷ º´¿ø¿¡¼­ ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ÀÓ»ó ȯ°æ¿¡ ÀûÀÀÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ³Ý°, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀº ¿öÅ©Ç÷οì¿Í Ä¡·á °á°ú¸¦ °³¼±Çϱâ À§ÇØ Åõ½Ã °Ë»ç¿Í CT, ÃÊÀ½ÆÄ, ³»ºñ°ÔÀÌ¼Ç ½Ã½ºÅÛÀ» ÅëÇÕÇÑ ¸ÖƼ¸ð´Þ À̹Ì¡ Ç÷§Æû¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿Ü·¡ Áø·á¼Ò ¹× ¿ø°Ý ÀÇ·á Áö¿øÀ» ÅëÇÑ Ä¡·áÀÇ ºÐ»êÈ­·Î ÀÎÇØ ÄÄÆÑÆ®Çϰí À̵¿¼ºÀÌ ¶Ù¾î³ª¸ç ºñ¿ë È¿À²ÀûÀÎ Åõ½Ã ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇ·áºñ ÁöÃâ Áõ°¡, ÁÖ¿ä ½ÃÀå¿¡¼­ÀÇ À¯¸®ÇÑ »óȯ Á¤Ã¥, Àåºñ Á¦Á¶¾÷ü¿Í º´¿ø ³×Æ®¿öÅ©¿ÍÀÇ Àü·«Àû Á¦ÈÞµµ ½ÃÀå °¡¼ÓÈ­¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, Á¤¹ÐÀÇ·á¿Í AI¸¦ Ȱ¿ëÇÑ Áø´ÜÀÇ ¹ßÀüÀ¸·Î Åõ½Ã °Ë»ç´Â °³ÀÎÈ­µÈ ½Ç½Ã°£, Àúħ½ÀÀû ÀǷḦ ½ÇÇöÇÏ´Â Áß¿äÇÑ ¼ö´ÜÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(°íÁ¤½Ä Åõ½Ã ÀåÄ¡, À̵¿½Ä Åõ½Ã ÀåÄ¡), ¿ëµµ(Á¤Çü¿Ü°ú, ½ÉÀåÇ÷°ü, ÅëÁõ °ü¸® ¹× ¿Ü»ó, ½Å°æÇÐ, ¼ÒÈ­±â, ºñ´¢±â, ÀÏ¹Ý ¿Ü°ú, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 36°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÍ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ÀÇ <>& Áß±¹ <>& ¸ß½ÃÄÚ <>& ij³ª´Ù <>&EU <>& ÀϺ» <>& Àεµ <>& ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Fluoroscopy Devices Market to Reach US$5.1 Billion by 2030

The global market for Fluoroscopy Devices estimated at US$4.1 Billion in the year 2024, is expected to reach US$5.1 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Fixed Fluoroscopes, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Mobile Fluoroscopes segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 7.2% CAGR

The Fluoroscopy Devices market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Fluoroscopy Devices Market - Key Trends & Drivers Summarized

Why Are Fluoroscopy Devices Regaining Prominence in Modern Medical Imaging?

Fluoroscopy devices are experiencing a resurgence in the global medical imaging landscape due to their real-time imaging capabilities that provide continuous X-ray visuals of moving internal structures. These devices have become indispensable in diagnostic and interventional procedures, particularly in cardiology, orthopedics, urology, gastroenterology, and pain management. Unlike static imaging methods such as CT or MRI, fluoroscopy allows physicians to observe live processes-like the movement of contrast agents, blood flow, or the manipulation of surgical instruments-making it vital for procedures such as catheter insertion, barium studies, and orthopedic joint evaluations. The increasing demand for minimally invasive surgeries has also expanded the use of fluoroscopy in image-guided interventions. In trauma care and emergency medicine, the ability to obtain immediate, dynamic imaging helps in faster and more accurate decision-making. Moreover, advancements in flat-panel detectors, digital imaging, and dose-reduction technologies have significantly improved the clarity, speed, and safety of fluoroscopy, enhancing its appeal to healthcare providers aiming to balance diagnostic accuracy with patient safety. The integration of mobile C-arms and compact systems into outpatient settings has further broadened access, positioning fluoroscopy as a vital and versatile tool in the continuum of care.

How Are Technological Advancements Driving Precision and Patient Safety?

Innovation in fluoroscopy technology is dramatically elevating the standard of care by improving image quality, reducing radiation exposure, and enabling integration with advanced procedural tools. Digital fluoroscopy systems with flat-panel detectors have largely replaced analog systems, offering higher resolution, faster processing, and better soft tissue visualization. Dose-reduction features-such as pulsed fluoroscopy, last image hold, and automatic exposure control-are helping mitigate long-standing concerns about radiation risks to both patients and healthcare workers. Additionally, software enhancements now enable real-time 3D reconstruction, motion correction, and image fusion with CT or MRI data, vastly improving anatomical accuracy during complex interventions. Integration with navigation systems and robotic surgical platforms is enabling precise targeting in vascular, neurological, and spinal procedures. Mobile C-arms have become more compact and powerful, allowing for enhanced flexibility in operating rooms, outpatient clinics, and even rural healthcare settings. Artificial intelligence is beginning to play a role in workflow automation, anomaly detection, and predictive analytics, optimizing both efficiency and diagnostic accuracy. These technological breakthroughs are ensuring that fluoroscopy devices remain at the forefront of image-guided therapy, delivering sharper diagnostics and safer procedural outcomes in increasingly diverse clinical settings.

Which Clinical Segments and Global Markets Are Leading in Adoption?

Fluoroscopy devices are in high demand across a broad spectrum of clinical specialties and care settings. Interventional cardiology and electrophysiology are among the largest segments, leveraging fluoroscopy for angiography, stent placements, and ablation procedures. Orthopedics and trauma surgery extensively use fluoroscopy for fracture reductions, joint replacements, and spinal instrumentation. Gastroenterology employs these devices for barium swallows, colon examinations, and feeding tube placements. Urology and gynecology benefit from real-time visualization during procedures like ureteral stent placement and hysterosalpingography. Pain management clinics rely on fluoroscopic guidance for epidural injections and nerve blocks. Regionally, North America holds the largest market share due to well-established healthcare infrastructure, high procedural volumes, and rapid adoption of advanced imaging technologies. Europe follows closely, with strong growth in Germany, the U.K., and France driven by aging populations and robust public healthcare systems. The Asia-Pacific region is emerging as a high-growth market, fueled by expanding hospital infrastructure, increased government investment in medical technology, and growing demand for minimally invasive procedures in countries like China, India, and South Korea. Latin America and the Middle East are gradually increasing adoption, particularly through private sector investment and public-private healthcare collaborations. These trends reflect a broadening global footprint and rising reliance on fluoroscopy across both developed and emerging healthcare ecosystems.

What Are the Critical Drivers Behind the Market’s Accelerated Growth?

The growth in the fluoroscopy devices market is driven by several factors rooted in technological evolution, procedural demand, and healthcare delivery transformation. First, the global rise in minimally invasive surgeries and image-guided interventions is propelling demand for real-time imaging tools that can enhance precision and reduce recovery times. Second, an aging population with increasing rates of chronic diseases-such as cardiovascular disorders, gastrointestinal issues, and musculoskeletal conditions-is generating higher volumes of fluoroscopy-dependent diagnostic and therapeutic procedures. Third, advancements in digital imaging, radiation dose control, and mobile fluoroscopy systems have made the technology safer and more adaptable for a wide range of clinical settings, from tertiary hospitals to ambulatory surgical centers. Fourth, healthcare providers are investing in multimodal imaging platforms that integrate fluoroscopy with CT, ultrasound, and navigation systems to improve workflow and treatment outcomes. Additionally, the decentralization of care-through outpatient clinics and telemedicine-assisted procedures-is expanding the need for compact, mobile, and cost-effective fluoroscopy solutions. Rising healthcare spending, favorable reimbursement policies in key markets, and strategic partnerships between equipment manufacturers and hospital networks are also contributing to market acceleration. Lastly, the ongoing push for precision medicine and AI-enabled diagnostics is positioning fluoroscopy as a critical enabler of personalized, real-time, and minimally invasive healthcare delivery.

SCOPE OF STUDY:

The report analyzes the Fluoroscopy Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Fixed Fluoroscopes, Mobile Fluoroscopes); Application (Orthopedic, Cardiovascular, Pain Management & Trauma, Neurology, Gastrointestinal, Urology, General Surgery, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â